



CHIMERIX

March 1, 2016

Chimerix to Present at Cowen and Company 36th Annual Health Care Conference

DURHAM, N.C., March 01, 2016 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing novel, oral antivirals to address unmet medical needs, today announced that M. Michelle Berrey, M.D., M.P.H., President and Chief Executive Officer of Chimerix, will present at the 36th Annual Cowen and Company Health Care Conference on Tuesday, March 8, 2016 at 8:00 a.m. ET at the Boston Marriott Copley Place.

A live audio webcast of the presentation will be available on the Investor Relations section of Chimerix's website at <http://ir.chimerix.com/events.cfm>, where it will be archived for approximately 90 days.

About Chimerix

Chimerix is a biopharmaceutical company dedicated to discovering, developing and commercializing novel, oral antivirals to address unmet medical needs. Chimerix's proprietary lipid conjugate technology has produced brincidofovir, a clinical-stage nucleotide analog, CMX157 which was licensed to ContraVir Pharmaceuticals in 2014, and early clinical candidates including CMX669. For further information, please visit Chimerix's website, www.chimerix.com.

CONTACT:

Investor Relations:

ir@chimerix.com

or

Jesse Baumgartner

Stern Investor Relations

Jesse@sternir.com

212-362-1200

Media:

Becky Vonsiatsky

W2O Group

bvonsiatsky@w2ogroup.com

413-478-2003



Source: Chimerix, Inc.

News Provided by Acquire Media